Eton Pharmaceuticals (NASDAQ:ETON) Releases Earnings Results

Eton Pharmaceuticals (NASDAQ:ETON) issued its quarterly earnings data on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.05), Zacks reports. The company had revenue of $24.27 million during the quarter, compared to analyst estimates of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%.

Here are the key takeaways from Eton Pharmaceuticals’ conference call:

• Eton reported a strong first quarter, with product sales up 73% year over year to $24 million and adjusted EBITDA of $5.7 million, while keeping spending growth relatively controlled.
• The company raised full-year 2026 revenue guidance to above $120 million from $110 million, citing outperformance in the base business plus early contributions from new launches.
• DESMODA and HEMANGEOL were highlighted as major growth drivers, with management saying DESMODA’s launch has been exceptionally strong and HEMANGEOL could become the company’s largest product by 2027.
• The company is making substantial commercial changes for HEMANGEOL, including a streamlined distribution model and a new patient support program with $0 co-pay support; management estimates about 60%–65% of volume may be near zero revenue, implying an average net price of roughly $8,000–$10,000 per patient.
• Eton advanced multiple pipeline programs, including FDA clearance to start an INCRELEX label-harmonization study, initiation of the ET-700 pilot study, progress on KHINDIVI label expansion, and an Amglidia filing pathway that could support a 2027 launch.

Eton Pharmaceuticals Trading Up 1.9%

Shares of ETON stock opened at $30.53 on Wednesday. Eton Pharmaceuticals has a 1-year low of $13.09 and a 1-year high of $35.66. The company has a market cap of $836.22 million, a price-to-earnings ratio of -436.08 and a beta of 0.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.21 and a quick ratio of 0.88. The stock has a 50 day simple moving average of $27.92 and a 200-day simple moving average of $20.81.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. HC Wainwright boosted their target price on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a research note on Friday, May 15th. B. Riley Financial raised their price target on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Tuesday, April 21st. Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. Finally, Zacks Research lowered shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 17th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $41.00.

Insider Transactions at Eton Pharmaceuticals

In related news, insider David Krempa sold 19,679 shares of Eton Pharmaceuticals stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total value of $619,298.13. Following the sale, the insider owned 25,249 shares of the company’s stock, valued at approximately $794,586.03. This trade represents a 43.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 100,000 shares of company stock valued at $3,229,921. 16.49% of the stock is currently owned by company insiders.

Institutional Trading of Eton Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Millennium Management LLC increased its stake in shares of Eton Pharmaceuticals by 156.3% during the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock worth $4,620,000 after purchasing an additional 217,042 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Eton Pharmaceuticals by 34.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock valued at $2,274,000 after buying an additional 45,341 shares in the last quarter. Jane Street Group LLC boosted its holdings in Eton Pharmaceuticals by 49.1% in the 1st quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock worth $1,245,000 after buying an additional 31,596 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Eton Pharmaceuticals by 114.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 242,580 shares of the company’s stock worth $3,457,000 after buying an additional 129,467 shares during the last quarter. Finally, Legal & General Group Plc purchased a new stake in Eton Pharmaceuticals during the 2nd quarter worth approximately $41,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.